Table 2 Characteristics of included studies in the meta-analysis
First author (year) | Country | Type of study | Primary diagnosis | Age, year (mean) | Subjects | Vitamin assessment | Intervention | Placebo type | Main outcomes | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Control/ Intervention | Sex (M, %) | Dose (g/day) | Duration (days) | ||||||||
Iglesias (2020) [23] | USA | RCT | Sepsis | 68.5 | 69/68 | 45 | AA | C1: 6 B1: 0.4 Hydrocortisone: 0.2 | 4 | Normal saline | PE: Vasopressors duration administration Null: – NE: Δ SOFA, mortality, LOS |
Chang (2020) [25] | China | RCT | Sepsis | 61.65 | 40/38 | 54 | – | C: 6 B1: 0.4 Hydrocortisone: 0.2 | 4 4 7 | Either normal saline or routine treatment | PE: – Null: Δ SOFA, hypernatremia NE: mortality, ICU LOS, vasopressors duration, length of Mechanical ventilation |
Donnino (2016) [31] | USA | RCT | Septic– shock | 67 | 45/43 | 59 | Thiamine | B1: 0.4 | 7 | Normal saline | PE: – Null: – NE: APACHE II, Δ SOFA, LOS, mortality |
Blakrishian (2019) [24] | India | RCT | Septic –shock | 52 | 12/12 | 62 | – | C: 6 B1: 0.4 Hydrocortisone: 0.2 | 4 | Normal saline | PE: Dose of noradrenaline and vasopressin Null: – NE: Δ SOFA, mortality |
Fujii (2020) [26] | Australia New-Zealand Brazil | RCT | Septic –shock | 61.7 | 104/107 | 63 | – | C: 6 B1: 0.4 Hydrocortisone: 0.2 | Up to 10 days | Hydro–cortisone: 0.2 | PE: – Null: – NE: Survival, vasopressors-free days, mortality, LOS, Δ SOFA, ventilator free days, ICU free days |
Harun (2019) [12] | Malaysia | RCT | Septic -shock | 65 | 33/32 | 58 | – | B1: 0.6 | 3 | Normal saline | PE: – Null: – NE: Vasopressors duration administration, ICU LOS, Δ SOFA, mortality |
Hwang (2020) [27] | Korea | RCT | Septic– shock | 70 | 58/53 | 38 | AA | C: Up to 6 B1: 0.4 | 2 | Normal saline | PE: – Null: Δ SOFA, mortality, vasopressor–free days, vasopressor dosage, ventilatorfree days NE: – |
Karimpour (2019) [28] | Iran | RCT | Septic- shock | 61 | 50/50 | 43 | – | C: Up to 6 B1: 0.2 | 4 | Normal saline | PE: vasopressors duration Null: Δ SOFA, mortality, ICU LOS, ventilator-free days NE: – |
Lomivorotov (2019) [13] | Australia | RCT | Surgery (CABG) | 64 | 20/19 | 59 | – | B1: 0.4 | 3 | Placebo | PE: – Null: vasopressor dose, length of mechanical ventilation, Δ SOFA, LOS, ICU LOS NE: – |
Luger (2015) [33] | Australia | RCT | Cardiac- Surgery | 58 | 15/15 | 77 | – | B1: 0.3 | Before surgery | Normal saline | PE: concentrations of blood thiamine Null: hospital LOS, 30 days- mortality, ICU LOS NE: – |
Moskowitz (2020) [29] | USA | RCT | Septic- shock | 68.4 | 99/101 | 55 | – | C: 6 B1: 0.4 Hydrocortisone: 0.2 | 4 | Normal saline | PE: – Null: Δ SOFA, mortality, ventilator-free days NF: – |
Moslemi (2020) [10] | Iran | RCT | Surgery | 54 | 48/48 | 59 | – | B1: 0.2 | 3 | Normal saline | PE: – Null: length of mechanical ventilation, vasopressor use, Δ SOFA NE: – |
Nasution (2020) [34] | Indonesia | RCT | Sepsis | 46 | 12/12 | – | – | B1: 0.4 | 3 | Normal saline | PE: – Null: Δ SOFA NE: – |
Pradita-ukrit (2020) [32] | Thailand | RCT | Cardiac-arrest | 64.3 | 17/20 | 70 | – | B1: 0.3 | 7 | Normal saline | PE: – Null: mortality, ICU LOS NE: – |
Wani (2020) [30] | India | RCT | Sepsis | 67.5 | 50/50 | 59 | – | C: 6 B1: 0.4 Hydrocortisone: 0.2 | 4 4 7 | Normal saline | PE: vasopressor duration Null: mortality, length of mechanical ventilation, vasopressor duration, LOS, Δ SOFA NE: – |